DE60023167D1 - Pyrazol-derivate als cannabinoidrezeptor-antagonisten - Google Patents

Pyrazol-derivate als cannabinoidrezeptor-antagonisten

Info

Publication number
DE60023167D1
DE60023167D1 DE60023167T DE60023167T DE60023167D1 DE 60023167 D1 DE60023167 D1 DE 60023167D1 DE 60023167 T DE60023167 T DE 60023167T DE 60023167 T DE60023167 T DE 60023167T DE 60023167 D1 DE60023167 D1 DE 60023167D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
cannabinoid receptor
pyrazol derivatives
pyrazol
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60023167T
Other languages
English (en)
Other versions
DE60023167T2 (de
Inventor
Alexandros Makriyannis
Qian Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Application granted granted Critical
Publication of DE60023167D1 publication Critical patent/DE60023167D1/de
Publication of DE60023167T2 publication Critical patent/DE60023167T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
DE60023167T 1999-10-18 2000-10-18 Pyrazol-derivate als cannabinoidrezeptor-antagonisten Expired - Fee Related DE60023167T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15999399P 1999-10-18 1999-10-18
PCT/US2000/041239 WO2001029007A1 (en) 1999-10-18 2000-10-18 Pyrazole derivatives as cannabinoid receptor antagonists

Publications (2)

Publication Number Publication Date
DE60023167D1 true DE60023167D1 (de) 2006-02-23
DE60023167T2 DE60023167T2 (de) 2006-06-14

Family

ID=22575021

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023167T Expired - Fee Related DE60023167T2 (de) 1999-10-18 2000-10-18 Pyrazol-derivate als cannabinoidrezeptor-antagonisten

Country Status (7)

Country Link
EP (1) EP1224173B1 (de)
JP (1) JP2003512357A (de)
AU (1) AU780572B2 (de)
CA (1) CA2387892A1 (de)
DE (1) DE60023167T2 (de)
MX (1) MXPA02005100A (de)
WO (1) WO2001029007A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69910373T2 (de) 1998-05-04 2004-04-01 The University Of Connecticut, Farmington Analgetische und immunomodulierende cannabinoiden
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
DE60033834T2 (de) 1999-10-18 2007-11-15 The University Of Connecticut, Farmington Für periphäre cannabinoid-rezeptoren selektive liganden
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
CA2468794A1 (en) * 2001-12-07 2003-06-19 Virginia Commonwealth University Treatment of neoplasia
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
AU2003250117B2 (en) * 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
CN1678303A (zh) 2002-08-23 2005-10-05 康涅狄格大学 具有治疗作用的酮类大麻类
US7319110B2 (en) * 2002-09-19 2008-01-15 Solvay Pharmaceuticals B.V. 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CN1832741A (zh) * 2003-08-07 2006-09-13 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
KR101496206B1 (ko) 2005-01-05 2015-02-27 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP2835367A1 (de) 2005-01-05 2015-02-11 AbbVie Inc. Inhibitoren des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms
AU2006205220B2 (en) * 2005-01-10 2012-09-13 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
WO2006074445A2 (en) * 2005-01-10 2006-07-13 Alexandros Makriyannis Novel heteropyrrole analogs acting on cannabiniod receptors
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
JP2009519349A (ja) 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
WO2007107470A2 (en) 2006-03-22 2007-09-27 F. Hoffmann-La Roche Ag Pyrazoles as 11-beta-hsd-1
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
KR20090069318A (ko) 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 조절하는 화합물
US8148404B2 (en) 2006-12-18 2012-04-03 7Tm Pharma A/S Modulators of CB1 receptors
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
KR20100072037A (ko) 2007-09-20 2010-06-29 애보트 헬스케어 프로덕츠 비.브이. 칸나비노이드 ｃｂ₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1ｈ)-피라졸
KR20110063438A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
EP2523936A1 (de) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Cb2 rezeptor-modulierende verbindungen
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
FR2978660B1 (fr) * 2011-08-05 2013-09-20 Oreal Utilisation d'antagoniste du recepteur cb1 en tant qu'agent blanchissant et/ou anti-brunissement des matieres keratiniques
RU2014141674A (ru) 2012-03-16 2016-05-10 Аксикин Фармасьютикалз, Инк. 3,5-диаминопиразоловые ингибиторы киназы
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
KR102034202B1 (ko) 2014-12-23 2019-10-18 에스엠에이 세라퓨틱스 아이엔씨. 3,5-디아미노피라졸 키나제 억제제
BR112020003725A2 (pt) 2017-10-06 2020-11-03 Forma Therapeutics, Inc. inibição da peptidase 30 específica de ubiquitina
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
SI3860989T1 (sl) 2018-10-05 2023-06-30 Forma Therapeutics, Inc. Kondenzirani pirolini,ki delujejo kot zaviralci ubikvitin-specifične proteaze (usp30)
GB2602019A (en) * 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
GB202208810D0 (en) * 2022-06-15 2022-07-27 Gw Res Ltd Crystaline forms of a synthetic cannabinoid
WO2024026359A1 (en) * 2022-07-26 2024-02-01 The Board Of Trustees Of The University Of Illinois Compounds and methods for the treatment of diseases associated with parasitic worms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
EP1176140B1 (de) * 1999-02-10 2004-12-29 Mitsubishi Pharma Corporation Amid-derivate und deren medizinische verwendung

Also Published As

Publication number Publication date
DE60023167T2 (de) 2006-06-14
EP1224173B1 (de) 2005-10-12
EP1224173A4 (de) 2002-11-20
EP1224173A1 (de) 2002-07-24
CA2387892A1 (en) 2001-04-26
MXPA02005100A (es) 2003-09-25
WO2001029007A1 (en) 2001-04-26
AU780572B2 (en) 2005-04-07
AU1968901A (en) 2001-04-30
JP2003512357A (ja) 2003-04-02

Similar Documents

Publication Publication Date Title
DE60023167D1 (de) Pyrazol-derivate als cannabinoidrezeptor-antagonisten
ATE253067T1 (de) Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
DE60218340D1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
DE60120419D1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE288898T1 (de) Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
DE60022386D1 (de) Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
DE60032601D1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
DE69939053D1 (de) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten
ATE416173T1 (de) 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4- benzylpiperidine als nmda-rezeptor-antagonisten
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
ATE221052T1 (de) Tetrahydrochinolinderivate als eaa antagonisten
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
NO20013997L (no) Reseptoranalyse
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE254621T1 (de) Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten
ATE244716T1 (de) Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten
DE60017110D1 (de) Biphenylderivate als neurokinin-1 antagonisten
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
DE69703242D1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
DE60003072D1 (de) Thiazolidindion-derivate als antidiabetika
ATE281456T1 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
DE60113525D1 (de) Propansäure-derivate als integrin-rezeptor-antagonisten
DE69717449D1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee